LY320135, a novel cannabinoid CB1 receptor antagonist, unmasks coupling of the CB1 receptor to stimulation of cAMP accumulation

Journal of Pharmacology and Experimental Therapeutics

Volumn 284, Issue 1, 1998, Pages 291-297

  Felder, Christian C ^c   Joyce, Kelly E ^a   Briley, Eileen M ^a   Glass, Michelle ^a   Mackie, Kenneth P ^b   Fahey, Kennan J ^c   Cullinan, George J ^c   Hunden, David C ^c   Johnson, Douglas W ^c   Chaney, Michael O ^c   Koppel, Gary A ^c   Brownstein, Michael ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 4 [6 METHOXY 2 (4 METHOXYPHENYL) 3 BENZOFURANYLCARBONYL]BENZONITRILE; ADENYLATE CYCLASE; ANANDAMIDE; CALCIUM CHANNEL; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; CYCLIC AMP; DEXANABINOL; PERTUSSIS TOXIN; RADIOLIGAND; RIMONABANT; TETRAHYDROCANNABINOL; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CEREBELLUM; CHO CELL; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; ENZYME INHIBITION; LIGAND BINDING; MOUSE; NONHUMAN; POTASSIUM CURRENT; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY; SPLEEN;

EID: 15144355924     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Casiano FM, Arnold R, Haychock D, Kuster J and Ward SJ (1990) Putative aminoindolealkyl antagonists. NIDA Res Monogr Ser 105:295-296.
2. ++ current in NG108-15 neuroblastoma cells via a pertussis toxin-sensitive mechanism. Br J Pharmacol 106:231-232.
3. Childers SR, Sexton T and Roy MB (1994) Effects of anandamide on cannabinoid receptors in rat brain membranes. Biochem Pharmacol 47:711-715.
4. Compton DR, Gold LH, Ward SJ, Balster RL and Martin BR (1992) Aminoalkylindole analogs: cannabimimetic activity of a class of compounds structurally distinct from delta 9-tetrahydrocannabinol. J Pharmacol Exp Ther 263:1118-1126.
5. Deutsch DG and Chin SA (1993) Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist. Biochem Pharmacol 46:791-796.
6. Devane WA, Dysarz FA, Johnson MR, Melvin LS and Howlett AC (1988) Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 36:605-613.
7. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A and Mechoulam R (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258:1946-1949.
8. Di Marzo V, Fontana A, Cadas H, Sehinelli S, Cimino G, Schwartz J-C and Piomelli D (1994) Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 372:686-691.
9. 9-tetrahydrocannabinol on the levels of cyclic adenosine 3′,5′-monophosphate in mouse brain. Biochem Pharmacol 23: 1817-1825.
10. Federman AD, Conklin BR, Schrader KA, Reed RR and Bourne HR (1992) Hormonal stimulation of adenylyl cyclase through Gi-protein beta gamma subunits. Nature 356:159-161.
11. Felder CC, Veluz JS, Williams HL, Briley EM and Matsuda LA (1992) Cannabinoid agonists stimulate both receptor- and non-receptor-mediated signal transduction pathways in cells transfected with and expressing cannabinoid receptor clones. Mol Pharmacol 42:838-845.
12. Felder CC, Briley EM, Axelrod J, Simpson JT, Mackie K and Devane WA (1993) Anandamide, an endogenous cannabinoid agonist, couples to receptor mediated signal transduction. Proc Natl Acad Sci USA 90:7656-7660.
13. Felder CC, Joyce KE, Briley EM, Mansouri J, Mackie K, Lai Y, Ma AL and Mitchell RL (1995) Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol Pharmacol 48:443-450.
14. Foreman MM, Fuller RW, Nelson DL, Calligaro DO, Kurz KD, Misner JW, Garbrecht WL and Parli CJ (1992) Preclinical studies on LY327733, a Potent and Selective Serotonergic Antagonist. J Pharmacol Exp Ther 260:51-57.
15. Hamill OP, Marty A, Neher E, Sakmann B and Sigworth FJ (1981) Improved patch-clamp techniques for high resolution current recording from cell and cellfree membrane patches. Pflugers Arch 391:85-100.
16. Hanus L, Gopher A, Almog S and Mechoulam R (1993) Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor. J Med Chem 36:3032-3034.
17. Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Coste BR and Rice KC (1991) Characterization and localization of cannabinoid receptors in rat brain: A quantitative in vitro autoradiographic study. J Neurosci 11:563-583.
18. Hillard CJ and Bloom AS (1983) Possible role of prostaglandins in the effects of cannabinoids on adenylate cyclase activity. Eur J Pharmacol 91:21-27.
19. Hillard CJ, Bloom AS and Houslay MD (1986) Effects of delta-9-tetrahydrocannabinol on glucagon receptor-coupling to adenylate cyclase in rat liver plasma membranes. Biochem Pharmacol 35:2797-2803.
20. 9-tetrahydrocannabinol on adenylate cyclase activation in heart. J Pharmacol Exp Ther 252:1075-1082.
21. Bowlett AC, Johnson MR, Melvin LS and Milne GM ( 1988) Nonclassical cannabinoid analgetics inhibit adenylate cyclase: Development of a cannabinoid receptor model. Mol Pharmacol 33:297-302.
22. Jones SVP, Heilman CJ and Brann MR (1991) Functional responses of cloned muscarinic receptors expressed in CHO-K1 cells. Mol Pharmacol 40:242-247.
23. 1-tetrahydrocannabinol on cyclic AMP in cultured human diploid fibroblasts. J Cyclic Nucleotide Res 5:303-313.
24. Lynn AB and Herkenham M (1994) Localization of cannabinoid receptors and nonsaturable high-density cannabinoid binding sites in peripheral tissues of the rat: Implications for receptor-mediated immune modulation by cannabinoids. J Pharmacol Exp Ther 268:1612-1623.
25. Mackie K and Hille B (1992) Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proc Natl Acad Sci USA 89:3825-3829.
26. Mackie K, Devane WA and Hille B (1993) Anandamide, an endogenous cannabinoid, inhibits N-type calcium currents in N18 cells as a partial agonist. Mol Pharmacol 44:498-503.
27. Mackie K, Lai Y, Westenbroek R and Mitchell R (1995) Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor. J Neurosci 15:6552-6561.
28. Martin BR (1986) Cellular effects of cannabinoids. Pharmacol Rev 38:45-74.
29. Matsuda LA, Lolait SJ, Brownstein MJ, Young A and Bonner TI (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346:561-564.
30. Mechoulam R (1986) Cannabinoids as Therapeutic Agents. CRC Press, Boca Raton, FL.
31. Munro S, Thomas KL and Abu-Shaar M (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature 366:61-65.
32. Pacheco M, Childers SR, Arnold R, Casiano F and Ward SJ (1991) Aminoalkylindoles: Actions on specific G-protein-linked receptors. J Pharmacol Exp Ther 257: 170-183.
33. Pertwee R, Griffen G, Fernando S, Li X, Hill A and Makriyannis A (1995) AM630, a competitive cannabinoid receptor antagonist. Life Sci 56:1949-1955.
34. Rinaldi-Carmona M, Barth F, Heaulme M, Shire D, Calandra B, Congy C, Martinez S, Maruani J, Neliat G, Caput D, Ferrara P, Soubrie P, Breliere JC and Le Fur G (1994) SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 350:240-244.
35. Shire D, Carillon C, Kaghad M, Calandra B, Rinaldi-Carmona M, Le Fur G, Caput D and Ferrara P (1995) An amino-terminal variant of the central cannabinoid receptor resulting from alternative splicing. J Biol Chem 270:3726-3731.
36. Tang W-J. and Gilman AG (1991) Type-specific regulation of adenylyl cyclase by G protein beta gamma subunits. Science 254:1500-1503.